<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04173520</url>
  </required_header>
  <id_info>
    <org_study_id>SCORE</org_study_id>
    <nct_id>NCT04173520</nct_id>
  </id_info>
  <brief_title>ELRIAH Score: A Simple Score for HCC Risk Stratification in CHC Patients With Cirrhosis or Advanced Liver Fibrosis Who Achieved SVR Following DAA Therapy</brief_title>
  <official_title>ELRIAH Score: A Simple Score for HCC Risk Stratification in CHC Patients With Cirrhosis or Advanced Liver Fibrosis Who Achieved SVR Following DAA Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Egyptian Liver Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Egyptian Liver Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      aimed to develop a scoring system to assess risk of developing HCC in a large cohort of
      chronic hepatitis C (CHC) patients with advanced hepatic fibrosis (F3) or cirrhosis (F4) with
      sustained virological response (SVR) after receiving direct acting antivirals (DAAs).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Current guidelines recommend biannual surveillance for hepatocellular carcinoma (HCC) in all
      patients with cirrhosis. However, risk of HCC incidence is not the same for different
      patients. The study aimed to develop a scoring system to assess risk of developing HCC in a
      large cohort of chronic hepatitis C (CHC) patients with advanced hepatic fibrosis (F3) or
      cirrhosis (F4) with sustained virological response (SVR) after receiving direct acting
      antivirals (DAAs).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2015</start_date>
  <completion_date type="Actual">October 30, 2019</completion_date>
  <primary_completion_date type="Actual">August 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of HCC incidence after viral clearance</measure>
    <time_frame>12-45 months after SVR</time_frame>
  </primary_outcome>
  <enrollment type="Actual">2326</enrollment>
  <condition>HCC</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DDA</intervention_name>
    <description>Follow up after SVR</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        2326 CHC patients (638 patients with F3 and 1734 with F4 stage)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  no history of previous HCC

          -  SVR after DAAs treatment

        Exclusion Criteria:

          -  history of previous HCC
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 17, 2019</study_first_submitted>
  <study_first_submitted_qc>November 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2019</study_first_posted>
  <last_update_submitted>November 22, 2019</last_update_submitted>
  <last_update_submitted_qc>November 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

